ARCALYST *
Manufacturer Details
REGENERON INC
Regeneron Pharmaceuticals Co. Inc
Compositions:
220mg Injection,
lyophilized powder for solution,
Strength
|
Rate
|
Packing Style
|
220mg
|
0.00
|
20ml in single use vial
|
List of Related Indications:
List Of Drugs:
- Rilonacept - @- Immunomodulators
Indication Type Description:
Drug Interaction:
Interactions - summary
CYP- 450 substrates- formation of CYP-450 enzymes is suppressed by increased levels of
cytokinase during chronic inflammation
TNF blocking agent + Riloncept
Rilonacept + TNF blocking agent
Coadmin of rilonacept with TNF blocking agent may result in increased risk of serious
infections. Co-admin is not recommended
Indication:
Treatment of crytopyrin- associated periodic syndrome
Adverse Reaction:
Most common adverse infection-
CNS - hypesthesia 8%
GI - abdominal pain diarrhea 3% nausea 3% stomach discomfort 3%
GU- urinary tract infection 3%
Local - injection site reactions 40%
Respiratory- cough 8% sinusitis 7% upper respiratory tract infection 25%
Contra-Indications:
Special precautions-
Infections- may interfere with imune response to infection.system. Taking rilonacept with
TNF inhibitors is not recommended since this may increase risk of serious infections
Immunosuppression- treatment with immunosupressants including rilonacept may result
in an increase in the risk of malignancies
Hypersensitivity - rare. if reactions occurs discontinue administration of rilonacept
Pregnancy- use rilonacept during pregnancy only if the benefit justifies the potent risk to fetus
Lactation- excercise caution when rilonacept is administered to breast feeding woman
Children- safety and effitiveness in children younger than 12 years have not been established
Elderly- In clinical studies,efficacy and tolerability generally similar in elderly patients
as compared to younger adults
Dosages/ Overdosage Etc:
Indication-
Treatment of crytopyrin- associated periodic syndrome
Dosage-
18 years and older - initial loading dose 320mg delivered as two 2ml subcutaneous injection
of 160mg each given on the same day at 2 different sites.
Dosing should be continued with once weekly injection of 160mg administerd as a single
2ml suncutaneous injection.
Rilonacept should not be gven more often than once weekly.
Patient Information:
1. Inform patients that they may experience injection site reactions- including, pain, eryhema,
swelling, pruritus, bruising, inflammation, dermatitis, edema, urticaria
2. Caution patients that rilonacept has been associated with serious life threatening infections
3. Patients should report any symptoms of infections or allergic reactions to their doctor.
Pregnancy and lactation:
Pregnancy-
Use rilonacept during pregnancy only if the benefit justifies the potent risk to fetus
Lactation-
Excercise caution when rilonacept is administered to breast feeding woman
Children-
Safety and effitiveness in children younger than 12 years have not been established
Elderly-
In clinical studies,efficacy and tolerability generally similar in elderly patients
as compared to younger adults